Australia thrashes out patient access deals for Soliris/Kalydeco
This article was originally published in Scrip
Executive Summary
The Australian authorities are to start funding the use of Alexion's Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) and Vertex' Kalydeco (ivacaftor) for cystic fibrosis under the Pharmaceutical Benefits Scheme (PBS) from 1 December.
You may also be interested in...
Cystic Fibrosis: Successes, Opportunities And Challenges
What is next for the treatment of cystic fibrosis, a rare disease market that has boomed in recent years on the back of new drug approvals with hefty price tags? Pipelines are full, but securing reimbursement is a challenge.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.